Erasca (ERAS) Assets Average (2021 - 2026)
Erasca posted quarterly Assets Average of $428.7 million for Q1 2026, down 11.95% year-on-year from $486.9 million in Q1 2025, and up 5.0% on a QoQ basis from $408.3 million in Q4 2025.
Erasca (ERAS) has 6 years of Assets Average data on file, last reported at $428.7 million in Q1 2026.
- For the quarter ending Q1 2026, Assets Average fell 11.95% year-over-year to $428.7 million; the trailing twelve-month figure through Mar 2026 stood at $428.7 million (down 11.95% YoY), and the FY2025 full-year result was $449.3 million, changed 0.1% from the prior year.
- Assets Average for Q1 2026 stood at $428.7 million, up from $408.3 million in the prior quarter.
- Across five years, Assets Average topped out at $527.3 million in Q3 2024 and bottomed at $382.7 million in Q1 2024.
- The 5-year median for Assets Average is $454.1 million (2023), against an average of $455.7 million.
- The widest annual swing landed in 2024, when Assets Average dropped 22.1%; it then gained 27.24% in 2025.
- A 5-year view of Assets Average shows it stood at $480.7 million in 2022, then decreased by 15.25% to $407.4 million in 2023, then advanced by 26.6% to $515.7 million in 2024, then decreased by 20.83% to $408.3 million in 2025, then rose by 5.0% to $428.7 million in 2026.
- The last three Assets Average figures came in at $428.7 million (Q1 2026), $408.3 million (Q4 2025), and $432.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 428.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 428.69 Mn |
| Dec 31, 2025 | 408.28 Mn |
| Sep 30, 2025 | 432.89 Mn |
| Jun 30, 2025 | 458.32 Mn |
| Mar 31, 2025 | 486.89 Mn |
| Dec 31, 2024 | 515.71 Mn |
| Sep 30, 2024 | 527.32 Mn |
| Jun 30, 2024 | 447.88 Mn |
| Mar 31, 2024 | 382.66 Mn |
| Dec 31, 2023 | 407.35 Mn |
| Sep 30, 2023 | 430.03 Mn |
| Jun 30, 2023 | 454.10 Mn |
| Mar 31, 2023 | 491.23 Mn |
| Dec 31, 2022 | 480.67 Mn |
| Sep 30, 2022 | 445.63 Mn |
| Jun 30, 2022 | 460.15 Mn |
| Mar 31, 2022 | 488.44 Mn |
| Dec 31, 2021 | 511.68 Mn |
| Sep 30, 2021 | 366.17 Mn |